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Traumatic brain injury triggers a series of complex pathophysiological processes.  These include abnormalities in brain energy
metabolism; consequent to reduced tissue pO2 arising from ischaemia or abnormal tissue oxygen diffusion, or due to a failure of
mitochondrial function. In-vivo magnetic resonance spectroscopy (MRS) allows non-invasive interrogation of brain tissue
metabolism in patients with acute brain injury. Nuclei with ‘spin’ e.g. 1H, 31P and 13C, are detectable using MRS and are found in
metabolites at various stages of energy metabolism, possessing unique signatures due to their chemical shift or spin-spin
interactions (J-coupling).
The most commonly used clinical MRS technique, 1H MRS, uses the great abundance of hydrogen atoms within molecules in brain
tissue. Spectra acquired with longer echo-times include N-acetylaspartate, creatine and choline. N-acetylaspartate, a marker of
neuronal mitochondrial activity related to ATP, is reported to be lower in patients with TBI than healthy controls, and the ratio of
N-acetylaspartate/creatine at early time points may correlate with clinical outcome. 1H MRS acquired with shorter echo-times
produces a more complex spectrum, allowing detection of a wider range of metabolites.
31P MRS detects high energy phosphate species, which are the end-products of cellular respiration: adenosine triphosphate (ATP)
and phosphocreatine. ATP is the principal form of chemical energy in living organisms, and phosphocreatine (PCr) is regarded as a
readily-mobilised reserve for its replenishment during periods of high utilisation.  The ratios of high energy phosphates are
thought to represent a balance between energy generation, reserve and use in the brain Additionally, the chemical shift difference
between Pi and PCr enables calculation of intracellular pH.
13C MRS detects the 13C-isotope of carbon in brain metabolites. As the natural abundance of 13C is low (1.1%),13C MRS is typically
performed following administration of 13C-enriched substrates which permits tracking of the metabolic fate of the infused 13C in
the brain over time, and calculation of metabolic rates in a range of biochemical pathways, including glycolysis, the tricarboxylic
acid (TCA) cycle, and glutamate-glutamine cycling. The advent of new hyperpolarization techniques to transiently boost signal in
13C-enriched MRS in-vivo studies shows promise in this field and further developments are expected.
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Abstract 34 
Traumatic brain injury triggers a series of complex pathophysiological processes.  These 35 
include abnormalities in brain energy metabolism; consequent to reduced tissue pO2 arising 36 
from ischaemia or abnormal tissue oxygen diffusion, or due to a failure of mitochondrial 37 
function. In-vivo magnetic resonance spectroscopy (MRS) allows non-invasive interrogation 38 
of brain tissue metabolism in patients with acute brain injury. Nuclei with ‘spin’ e.g. 1H, 31P 39 
and 13C, are detectable using MRS and are found in metabolites at various stages of energy 40 
metabolism, possessing unique signatures due to their chemical shift or spin-spin interactions 41 
(J-coupling). 42 
 43 
The most commonly used clinical MRS technique, 1H MRS, uses the great abundance of 44 
hydrogen atoms within molecules in brain tissue. Spectra acquired with longer echo-times 45 
include N-acetylaspartate, creatine and choline. N-acetylaspartate, a marker of neuronal 46 
mitochondrial activity related to ATP, is reported to be lower in patients with TBI than 47 
healthy controls, and the ratio of N-acetylaspartate/creatine at early time points may correlate 48 
with clinical outcome. 1H MRS acquired with shorter echo-times produces a more complex 49 
spectrum, allowing detection of a wider range of metabolites. 50 
 51 
31P MRS detects high energy phosphate species, which are the end-products of cellular 52 
respiration: adenosine triphosphate (ATP) and phosphocreatine. ATP is the principal form of 53 
chemical energy in living organisms, and phosphocreatine (PCr) is regarded as a readily-54 
mobilised reserve for its replenishment during periods of high utilisation.  The ratios of high 55 
energy phosphates are thought to represent a balance between energy generation, reserve and 56 
use in the brain Additionally, the chemical shift difference between Pi and PCr enables 57 
calculation of intracellular pH. 58 
 59 
13C MRS detects the 13C-isotope of carbon in brain metabolites. As the natural abundance of 60 
13C is low (1.1%),13C MRS is typically performed following administration of 13C-enriched 61 
substrates which permits tracking of the metabolic fate of the infused 13C in the brain over 62 
time, and calculation of metabolic rates in a range of biochemical pathways, including 63 
glycolysis, the tricarboxylic acid (TCA) cycle, and glutamate-glutamine cycling. The advent 64 
of new hyperpolarization techniques to transiently boost signal in 13C-enriched MRS in-vivo 65 
studies shows promise in this field and further developments are expected. 66 
  67 
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Introduction 68 
Metabolic dysfunction in TBI 69 
Traumatic brain injury (TBI) is the commonest cause of death and disability in young adults 70 
in the developed world and is a significant demand on resources[1]. If a person survives the 71 
initial traumatic insult a series of pathophysiological processes occur causing further damage 72 
to the brain that results in greater disability and even death. These include raised intracranial 73 
pressure (ICP), cerebral hypoperfusion, generalised hypoxia, hypoglycaemia, 74 
neuroinflammation and metabolic dysfunction. Metabolic dysfunction describes the brain 75 
relying on glycolysis (despite the presence of oxygen) as a rapid but inefficient means of 76 
synthesising ATP – so generating much less ATP per mole of glucose consumed than if the 77 
pyruvate produced by glycolysis feeds into mitochondrial metabolism. It is often ascribed to a 78 
failure of mitochondrial function[2], [3]. Due to advances in neurointensive care and 79 
multimodality monitoring gross hypoxia and hypoperfusion are generally avoided in patients, 80 
and raised intracranial pressure is identified and managed. The monitoring, interpretation and 81 
treatment of brain metabolic dysfunction and neuroinflammation are more challenging. 82 
 ‘Normal’ energy metabolism of the human brain consists of a complex interaction of 83 
multistep processes with trafficking of metabolites between different cells types. In each 84 
section of our review (1H, 31P, 13C) we describe the pathways relevant to the technique, and 85 
for review see [4], [5]. It should be noted that normal human brain metabolism remains a 86 
subject of research and is still not fully understood, but glucose is invariably considered the 87 
principal metabolic fuel for the brain. A simplified schematic of major energy pathways in 88 
the brain is shown in Fig 1. After uptake into the brain, most of the glucose is metabolised via 89 
glycolysis into two molecules of pyruvate, with a net production of two molecules of ATP 90 
and two molecules of NADH in the process. A smaller proportion of glucose is metabolised 91 
via the pentose phosphate pathway (PPP). The PPP is a complex detour starting from 92 
glucose-6-phosphate (hence its alternative name “hexose monophosphate shunt”) bypassing 93 
some of the steps of glycolysis in the metabolism of glucose. The PPP does not require 94 
molecular oxygen, and it does not consume or produce ATP. During the PPP, the first carbon 95 
of glucose is lost as CO2, NADP+ is reduced to NADPH, and various intermediates are 96 
produced, including ribose-5-phosphate used in the synthesis of nucleotides and nucleic 97 
acids. NADPH participates in reductive reactions such as synthesis of fatty acids and the 98 
reduced form of glutathione, a cofactor for glutathione peroxidase. Thus, the PPP has been 99 
suggested to play a protective role after TBI, promoting synthesis of molecules for tissue 100 
repair and combatting oxidative stress.  The PPP therefore sacrifices some of the carbon of 101 
glucose for the sake of tissue repair. The PPP ultimately re-joins the glycolysis mainstream, 102 
and pyruvate may then be incorporated into the TCA cycle in cell mitochondria after 103 
conversion to acetyl CoA, where it is metabolised through eight steps, generating three 104 
molecules of NADH, one FADH2 and a molecule of GTP. FADH2 and NADH drive the 105 
electron transport chain at the mitochondrial membrane, producing ATP from ADP by 106 
oxidative phosphorylation in the presence of oxygen. ATP is the fundamental molecule of 107 
chemical energy in humans and is used to drive cellular reactions and machinery, being 108 
converted back to ADP and Pi in the process. As an alternative to mitochondrial metabolism, 109 
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pyruvate may stay in the cytosol and be converted to lactate (by the action of lactate 110 
dehydrogenase), recycling the NADH produced in glycolysis back to NAD+, so allowing 111 
glycolysis to continue. The conversion (chemically, an oxidation) of NADH to NAD+ in the 112 
cytosol can also be accomplished by the action of the electron transport chains of 113 
mitochondria, if operational. As NADH cannot itself cross the mitochondrial membrane, the 114 
requisite hydrogens and electrons are transferred indirectly by “shuttle” mechanisms. For 115 
more information on the above biochemical pathways in the context of brain [6]–[8]. 116 
Studies using a range of techniques have shown that the human brain will take up and directly 117 
metabolise alternative fuels such as lactate, acetate, beta-hydroxybutyrate and ketone bodies 118 
[4], [5], [9]. Shuttling of fuels is also thought to occur between different cell types: the 119 
astrocyte-neuron-lactate shuttle hypothesis suggests that astrocytes take up glucose from the 120 
blood supply, convert it to lactate, then feed that to their surrounding neurons for conversion 121 
back to pyruvate and then metabolism by the TCA cycle [10]. A further neuronal-astrocyte 122 
coupling is the glutamate-glutamine cycle, whereby TCA cycle intermediate α-ketoglutarate 123 
is converted to glutamate for neurotransmission. After glutamate is released it is taken up by 124 
local astrocytes, converted to glutamine, and then fed back to the neurons for conversion back 125 
to glutamate and thence to alpha-ketoglutarate, which can re-enter (termed anaplerosis) into 126 
the TCA cycle, or else glutamate can be released for further neurotransmission [5]. 127 
Disruption and changes to human brain metabolism following acute severe traumatic brain 128 
injury depend on injury severity and how long after the injury occurred. In the acute phase a 129 
depression of the metabolic rate of glucose and a fall in oxygen consumption is generally 130 
reported [11]. Brain extracellular lactate may rise following TBI [3], [6], but because lactate 131 
is a recognised brain fuel, changes to its absolute concentration are difficult to interpret. More 132 
useful is the ratio of lactate/pyruvate as the exchange of these species are at fast equilibrium, 133 
directly proportional to the ratio of NADH/NAD+ (redox state of the cell) which correlates 134 
with outcome following TBI [3], [12]. 135 
The metabolic state of the brain and markers of degree of injury can be interrogated with 136 
magnetic resonance spectroscopy (MRS), microdialysis, positron emission tomography 137 
(PET) and arterio-venous (AV) difference measurements of metabolites. The limitations of 138 
microdialysis are its invasive nature involving insertion of intracerebral catheters, its 139 
sampling is confined to the extracellular compartment and its highly focal nature means that 140 
generalisation to the rest of the brain is uncertain. PET is relatively less invasive and reflects 141 
the intracellular and extracellular compartments of the brain, but involves the exposure of 142 
patients to intravenously injected radioactive (short half-life) ligands, and is usually 143 
combined with CT or MRI to enable optimal localisation of the PET signal. AV difference 144 
studies are invasive and have become less convenient as jugular bulb venous catheters are 145 
nowadays not routinely used in the management of patients with acute TBI[2]. 146 
Prognosticating in severe TBI can also be difficult. Patient age, neurological status at 147 
presentation and cardiovascular stability are known to correlate statistically with outcome at 148 
six months[1] but are unable to reliably predict outcome in every individual case. Other 149 
biomarkers for prognostication include ICP and the marker of metabolic dysfunction, L/P 150 
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ratio, which is measured by microdialysis[2]. Further prognostic markers that can strengthen 151 
existing predictive models of outcome will allow more informed decisions from relatives and 152 
clinicians for ceilings of treatment and standardisation of injury severity in research studies 153 
and clinical audit[1], [2]. 154 
In-vivo MRS allows interrogation of key aspects of brain metabolism and has prognostic 155 
value. It is non-invasive, does not involve ionizing radiation and measures metabolites from 156 
whole brain tissue; both the extracellular compartment and also the intracellular compartment 157 
(which contributes 80% of total brain volume[13], [14]) of the region selected. Currently its 158 
use is limited to research but this review will discuss the changes in brain metabolites and 159 
biomarkers measured by in-vivo MRS following acute severe TBI, its potential for clinical 160 
monitoring to guide treatment, and its value as an additional prognostic tool. A limitation of 161 
scan-based technologies such as MRS (also MRI, CT and PET) is that they give “snapshots” 162 
done usually just once or twice during each patient‘s neurocritical care, and the question 163 
arises of optimally integrating scan-based data with continuous bedside monitoring 164 
modalities [2]. A detailed description of magnetic resonance physics is outside the scope of 165 
this review and can be found in the literature[15]–[17]. However, we cover a simplified 166 
explanation of the relevant basic science of MRS and practical considerations of scanning 167 
patients with acute severe TBI. 168 
 169 
Magnetic resonance spectroscopy 170 
Certain nuclei possess a property termed “spin” that enables detection by magnetic resonance 171 
(MR). Examples include 1H, 31P and 13C (which all possess spin of ½). Nuclei with zero spin, 172 
e.g. 12C, cannot be detected by MR. For illustration, nuclei with spin can be considered as 173 
tiny, atomic, bar magnets. MR detection relies on the principle that when a population of 174 
magnetic nuclei is placed in an external magnetic field, the nuclei become aligned in a 175 
predictable number of orientations. For 1H (likewise 13C or 31P) there are two orientations: 176 
with or against the external magnetic field. Since the with-field orientation is preferred as 177 
lower energy, slightly more of the population of nuclei are aligned with the field than against 178 
the field. Some spins align against the field, as the nuclei are very weak magnets and the 179 
energy difference between the two orientations – with and against the external field - is not 180 
large, even in a strong external magnetic field. There is enough thermal energy at 181 
physiological temperature for nuclei to exchange between the two orientations, though with a 182 
slight excess on average in the lower energy (aligned with field) state. MR spectroscopy 183 
measurement applies energy as radio-frequency (RF) electromagnetic radiation to excite the 184 
small excess of with-field oriented nuclei into the against-field higher energy state. When the 185 
RF is removed, the energized nuclei relax back to the lower-energy with-field state, and in 186 
doing so the relaxing nuclei create their own fluctuating magnetic field. This induces a 187 
current in the receiver coil that is around the “sample” (e.g. brain). This current constitutes a 188 
signal that is electronically converted into a peak in the spectrum. 189 
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For the signal from a nucleus to be detected by in-vivo MRS the molecule in which it is 190 
present must be sufficiently mobile and free to tumble. In the case of nuclei that are bound up 191 
in large macromolecules or closely confined by cellular membranes, the spins of the nuclei 192 
relax (by spin-spin interaction with other nuclei) too quickly for detection and 193 
characterization by in-vivo MRS. 194 
The radio-frequency needed to excite the nucleus depends on what isotope it is (e.g. 1H, 31P 195 
or 13C), its chemical environment and the strength of the external magnetic field, i.e. the 196 
scanner magnet [9]. The radio-frequency needed to excite the nucleus is directly proportional 197 
to both the strength of the external magnetic field and the gyromagnetic ratio (see Table 1) of 198 
the isotope. The effect of chemical environment is relatively much smaller, but readily 199 
measurable. It is due to greater or lesser shielding of the nucleus from the main (external) 200 
magnetic field by the electrons surrounding the nucleus. This electron shielding results in 201 
small changes of the frequency of the MR signal detected and is called the chemical shift, 202 
usually expressed as parts per million (ppm; Hz per MHz). It is the same at all field strengths 203 
and is the basis for metabolite identification using MRS. In principle, a peak will be observed 204 
for every magnetically distinct nucleus in a molecule because nuclei that are not in identical 205 
structural situations do not experience the same shielding, and therefore experience slight 206 
differences in external magnetic field. 207 
MRS spectra are typically plotted with chemical shift along the x-axis with increasing 208 
(positive) chemical shift values reading from right to left (Fig 2 & 3). The y-axis represents 209 
signal intensity. The size (height, area) and shape of a peak is dependent on the concentration 210 
of metabolite(s) that it represents, relaxation time (T1/T2) effects, and splitting by spin-spin 211 
coupling. The latter, termed J-coupling, which occurs most strongly between magnetic nuclei 212 
that are adjacent to each other causes splitting of their spectral peaks (some splitting by more 213 
distant nuclei can also occur). J-coupling can reveal further information about the structure of 214 
a nucleus’s molecular environment, but in practice resolution is rarely sufficient with in-vivo 215 
MRS to fully separate a multiplet and so the effect of peak splitting usually just broadens the 216 
signal and reduces peak height relative to baseline noise. Spectra can be simplified by 1H 217 
decoupling which may be necessary in some applications (see later section on 13C MRS), but 218 
is of limited value in others (31P MRS). 219 
As signal frequency differences are used for chemical shift metabolite identification and not 220 
for spatial encoding, alternative methods of localisation must be used to exclude erroneous 221 
signal from non-neural tissue and acquire spectra from chosen regions of interest: a single 222 
voxel of brain can be selected using dedicated pulse sequences and gradient magnetic fields 223 
such as point resolved spectroscopy (PRESS), or multi-voxel chemical shift imaging (CSI) 224 
that uses phase encoding to sample spectra from multiple voxels at the same time (Figs 2 & 225 
3) [18], [19]. Outer volume suppression can also be used to suppress signal from scalp and 226 
bone[20], and where on a patient’s head a surface coil is placed will affect the region of the 227 
brain that it samples. Surface coils (Fig 4A) are more sensitive than volume coils (Fig 4B) 228 
that envelope the head, but suffer from a less homogenous delivery of RF pulse to the brain. 229 
Due to the different frequencies of 1H, 31P and 13C, they each require dedicated RF coils that 230 
are tuned to their respective frequencies (see Table 1). 31P and 13C coils will typically contain 231 
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an additional 1H channel within their housing however for simple brain imaging to localise 232 
the spectra, and for decoupling. 233 
MR scanners are generally classified by their magnetic field strength. Most clinical scanners 234 
are either 1.5 T or 3 T which are sufficient for standard MRS studies but higher fields such as 235 
7 T or 9.4 T exist. Higher field strength generally results in better spectral resolution and 236 
signal-to-noise ratio, but comes with the trade-off of greater magnetic field inhomogeneity 237 
and RF power deposition into the body resulting in greater tissue heating[21], [22]. 238 
In-vivo MRS studies often express metabolite concentrations as ratios of one another. 239 
Whereas the peak area of an MRS spectrum is proportional to the number of excited nuclei 240 
within the measurement volume, it is also affected by a variety of other variables: the timing 241 
of pulse sequences and their interaction with relaxation times, magnetic field inhomogeneity, 242 
and particularly RF coil loading which will vary between subjects and with coil position[23]. 243 
To compensate for all these effects is technically very challenging, even with external 244 
phantoms, as the latter may not accurately mimic tissue properties, and some biochemicals 245 
may be unstable. Expressing metabolites as ratios removes the need for units and calibration. 246 
although ratios can be more difficult to interpret than absolute concentrations. Application of 247 
an artificial reference pseudo-signal is an approach that shows promise for absolute 248 
quantification of concentrations in MRS[23]. 249 
Quantification of MRS signals, whether absolute or ratios, requires fitting of the spectral 250 
peaks. Simple integration to measure peak areas is not adequate in MRS as there is overlap 251 
between signals and the spectra are further complicated by noise. Therefore, MRS data are 252 
fitted using specialised algorithms that are available as various software packages, e.g. 253 
LCModel [24], jMRUI[25], [26] and, Syngo on Siemens scanners (Siemens Healthcare 254 
GmbH, Erlangen, Germany). 255 
 256 
1H MRS 257 
Hardware and sensitivity 258 
As MR imaging of the brain employs the detection of the 1H nucleus in water standard 259 
clinical head coils can perform 1H MRS. With its relatively high sensitivity, this has resulted 260 
in 1H MRS being the most studied spectroscopy technique in the investigation and 261 
monitoring of TBI.  262 
1H can be found in most organic molecules, but for a metabolite to be detected by in-vivo 1H 263 
MRS it must be present at millimole per litre (mmol / L) concentrations and be freely mobile: 264 
not bound to or closely confined by membranes or macromolecules. If it is, the signal from its 265 
1H signal decays away too quickly and is either not detected or lost in the baseline [27]. As 266 
the concentration of water in the brain is ≈ 50,000 mmol / L 1H MRS requires water 267 
suppression to stop the huge water peak dominating the spectrum, masking the other 268 
metabolites of interest [28]. 269 
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1H MRS is typically performed with a long echo time (TE) of around 120-150 ms[29] which 270 
reveals a simplified spectrum of N-acetylaspartate (NAA), choline, creatine and lactate[30]. 271 
Using a very short echo time of around 20-35 ms [28], [31], [32] allows detection of species 272 
whose magnetisation, and therefore signal, decays more rapidly: glutamate, glutamine, myo-273 
Inositol and lipids. However, the gain in information comes with increased spectral 274 
complexity. 275 
Creatine  276 
The creatine singlet peak at 3.0 ppm in the 1H spectrum represents both creatine and its 277 
phosphorylated form phosphocreatine. These are found in high concentrations in 278 
metabolically active tissues that require energy in bursts such as brain, muscle and heart. 279 
Phosphocreatine (PCr) may rapidly donate its phosphate group to adenosine diphosphate 280 
(ADP), rapidly regenerating adenosine triphosphate (ATP) by becoming creatine. In health, 281 
creatine is thought to vary less than other 1H MRS metabolites throughout the brain so it is 282 
the most commonly used denominator when expressing 1H metabolite ratios[33]. 283 
Phosphocreatine can also be detected by 31P MRS (see later section on 31P MRS). 284 
Effect of TBI 285 
Despite creatine being often regarded as a stable brain metabolite, enzyme extraction studies 286 
of rat traumatic brain injury have shown significant decline (up to 45 %) in brain creatine 287 
hyper-acutely following TBI[34]. Conversely, in a human study of mild TBI, creatine was 288 
found to be elevated in the splenium of the corpus callosum and white matter of the cingulate 289 
gyrus than in healthy controls, thought to be due to higher energy demand after TBI.[35]. 290 
Many studies do not report a change in creatine after TBI hence creatine is often used as an 291 
internal reference for measurement of other metabolites, but these examples demonstrate that 292 
the possibility of changes in creatine concentration cannot be ruled out when relying on it as a 293 
reference ratio. 294 
 295 
N-acetylaspartate 296 
The NAA peak at 2.0 ppm is a singlet that represents NAA and its product N-297 
acetylaspartyglutamate (NAAG), whose small peak is not resolved from the main NAA peak. 298 
NAA is formed from aspartate and acetyl-CoA by L-aspartate N-acetyltransferase which are 299 
associated with endoplasmic reticulum, or by splitting of N-acetyl-aspartyl-glutamate by N-300 
acetylated-a-linked-amino dipeptidase [27], [29]. Its specific role is not fully understood but 301 
it is closely associated with mitochondria and ATP[36]. NAA is found predominantly in 302 
neurons, and is thought to be a marker of neuron viability where it is transported down their 303 
axons, released, and taken up by oligodendrocytes where it is broken down into acetate and 304 
aspartate[35], [37]. The role of NAA in myelin lipid synthesis, particularly in early 305 
development, is well established. The acetic acid from NAA becomes incorporated into CNS 306 
myelin[38]. Under metabolic stress, a shortage of acetyl-CoA could result in reduced NAA 307 
synthesis and increased hydrolysis of NAA to provide acetate for myelin repair [39], [40]. 308 
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Among other functions ascribed to NAA is the idea that it is involved in osmoregulation[41]. 309 
Normally, NAA/Cho ratios are higher in grey matter than white matter[29] and can be low 310 
due to any cause of neuronal loss. NAA concentrations can be up to 7.5 - 17 mmol / L in 311 
brain; equal to that of the main excitatory neurotransmitter glutamate[15], [35].  312 
Early changes after TBI 313 
Studies of hyper-acute changes to brain metabolism following TBI are generally limited to 314 
experimental animal models due to the time delay transferring patients to hospital and 315 
stabilising them before MRS can be performed. Animal studies showed that a rapid fall of 316 
NAA within the first hours following TBI proportionally to the severity of the insult, and can 317 
reach its lowest level at 48 hours after injury[42]–[44]. This initial rapid decline in NAA 318 
following TBI likely represents a disruption in neuronal NAA production through general 319 
micro-architectural disruption and mitochondrial dysfunction[35], [43]. Human studies of 320 
patients with acute severe TBI performed within 24 hours also show a reduction in NAA, 321 
NAA/creatine and NAA/choline compared to healthy controls[45]–[49].  Another study of 10 322 
patients with moderate-severe TBI studied slightly later, after 48 - 72 hours after injury also 323 
found a reduction in NAA in 1H MRS compared to healthy volunteers, and the reduction was 324 
correlated with injury severity (GCS at presentation)[50].  325 
1H MRS performed in the sub-acute period around one week following acute severe TBI 326 
typically demonstrate persisting lower NAA/creatine ratios than healthy controls [29], [51], 327 
[52] which continued to fall in one study [29]. Interrogation of peri-lesional brain typically 328 
showed even greater NAA decline through the subacute period, beyond ten days[29]. 329 
Later changes after TBI 330 
If the primary injury is not too severe or compounded by further metabolic stress such as 331 
hypoxia or hypoperfusion, mitochondrial function and NAA may recover over the preceding 332 
days and months[42] with preservation of the neuron population. If the injury is more severe, 333 
there is likely irreversible physical and metabolic damage to the neurons which leads to a 334 
significant decline in neuronal population and therefore no recovery of NAA on MRS studies. 335 
Studies of delayed 1H MRS performed in the chronic, recovery phase after acute TBI either 336 
show recovery of NAA back to the levels seen in healthy controls in patients who make a 337 
good recovery or a persisting depression of NAA measured by 1H MRS in patients with poor 338 
long term neurological outcome[29], [53]. An exception to this is regions of brain 339 
surrounding significant traumatic lesions which tend not to recover despite patients having a 340 
good recovery [29], and a study by Garnett who found persisting NAA depression in all 341 
patients, regardless of outcome[51]. Contrastingly in other pathologies, partial recovery of 342 
brain NAA levels was reported using 1H-MRS in a small follow-up study of acute brain 343 
damage (non-TBI) patients[54]. 344 
Chronic NAA depression may affect white matter more than grey matter following severe 345 
TBI, as studies of patients at six weeks to six months after TBI found reduced NAA in the 346 
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white matter and not grey matter[53], [55]. This may also be explained by most studies 347 
selecting regions of the brain predominantly represent white matter and the corpus callosum. 348 
Role in clinical care 349 
Measuring NAA using 1H MRS can be clinically valuable due to its correlation with patient 350 
prognosis: the severity of depression of NAA/total metabolites[50], NAA/Cho[29] and 351 
NAA/Cr[51], [56] measured in the acute and sub-acute phase of injury correlates with patient 352 
outcome. Whereas these studies predominantly selected subcortical white matter and corpus 353 
callosum, the recovery of NAA in the thalami of TBI patients acutely after injury has been 354 
shown to predict good outcome[57]. Another study of brainstem 1H MRS in 40 patients with 355 
severe TBI showed that at a median 17 days after injury NAA/Cr ratio could predict very 356 
poor outcome in some patients that did not have visible injury on MRI. Furthermore, when 357 
included in a principal component analysis with FLAIR and T2* imaging, MRS allowed 358 
accurate prediction of GOS I-II, GOS III and GOS IV-V outcomes when these modalities 359 
alone could not[58]. 360 
Choline 361 
The choline peak at 3.2 ppm is formed from free choline, phosphocholine and 362 
glycerophophocholine[15]. Choline is a precursor of acetylcholine; an important 363 
neurotransmitter that is also found at high concentrations bound to cell membrane 364 
phospholipids. In its bound form its T2 is too short for detection, but when it is liberated 365 
during cell membrane turnover or cellular production of acetylcholine it becomes visible. An 366 
increase in choline is used to identify increases in cell membrane turnover or destruction in 367 
aggressive brain tumours and demyelinating disease, but in normal brain it is found at 0.5 – 368 
2.5 mmol / L[15]. 369 
Early changes after TBI 370 
Following TBI a raised choline is thought to represent cellular damage through membrane 371 
breakdown. Elevated choline/creatine compared to healthy controls has been found both sub-372 
acutely after injury and in the chronic phase[51], [59]. Garnett et al. found choline/creatine 373 
increased in proportion to the severity of injury in normal appearing white matter[51] but 374 
Wild et al. found no such correlation[59], although this could be due to changes in creatine 375 
blunting the effect of any relative change. An elevation of choline/total metabolites has been 376 
demonstrated within 48 - 72 hours of moderate-severe TBI, but this also did not correlate 377 
with presentation GCS or outcome at 3 months[50]. 378 
Later changes after TBI 379 
1H MRS performed in the subacute period following moderate-minor TBI of 40 patients 380 
found elevated choline/NAA ratio throughout the cerebrum and cerebellum[58]. However, 381 
there was an inverse relationship with outcome as patients with higher choline/NAA ratios 382 
had better cognitive performance at recovery. Delayed choline measurement during the 383 
chronic phase of severe TBI recovery often demonstrate persisting elevated choline/creatine 384 
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and reduced NAA/choline[51], [53] that sometimes correlates with functional status at the 385 
time[60]. 386 
Role in clinical care 387 
Choline can potentially be used as a predictor for TBI prognosis. A study of 42 patients with 388 
sub-acute (7 days post injury) severe TBI found that choline elevation in occipital grey and 389 
parietal white matter predicted outcome with 94% accuracy[32]. However, a separate smaller 390 
study (10 patients) performed in the acute period (48-72 hours) did not find a correlation with 391 
degree of choline elevation and outcome[50]. It is not clear why the magnitude of the acute 392 
choline rise does not correlate with the severity of the initial injury or later functional 393 
outcome of the patient. Delayed choline measurements tend to be more closely associated 394 
with outcome[32], [51] which may be because choline represents active neuroinflammation 395 
causing further cell membrane disruption and injury, well after the initial TBI[61], [62]. If 396 
this is the case, 1H MRS could be used to identify patients at risk of neuroinflammation; 397 
selecting them for potential new anti-neuroinflammatory therapeutic agents[63]. 398 
Myo-inositol  399 
Myo-inositol is a precursor of both phosphatidylinositol and phosphatidylinositol 4,5-400 
bisphosphate. Its 1H MRS peak is at 3.56 ppm and normal concentration in the brain is 4.0 – 401 
9.0 mmol / L. It is regarded as a cerebral osmolyte and astrocyte marker. Variable changes 402 
are seen in different intracranial pathologies: an absolute decrease may be seen in stroke and 403 
hepatic encephalopathy, likely due to imbalance of osmoregulation, while an increase in my-404 
inositol is found in astrogliosis, although when this is expressed as a ratio of myo-405 
inositol/creatine the effect disappears[64]. 406 
Effect of TBI 407 
Pascual et al. showed that myo-inositol can increase in the first 24-48 hours after TBI in a rat 408 
model[65]. A study of 38 paediatric TBI patients showed occipital grey matter myo-inositol 409 
levels were increased in children with TBI compared to healthy controls and that higher myo-410 
inositol levels correlated with poor outcome[66]. 411 
Glutamate & glutamine  412 
Glutamate (Glu) and glutamine (Gln) are amino acids found in abundance in the human brain 413 
detected at 2.2 - 2.4 ppm in a 1H MRS spectrum. Glutamate is the main excitatory 414 
neurotransmitter in the brain and is stored in neuron vesicles, found at a concentration 415 
between 6.0 - 12.5 mmol / L  in healthy human brain[15]. After release it is taken up by glia 416 
and converted to glutamine which is then fed back to neurons in the glutamate-glutamine 417 
cycle[67]. Glutamine is found in the brain at concentrations of 3.0 – 6.0 mmol / L[15]. The 418 
molecular structure of Glu and Gln are sufficiently similar that it is difficult to distinguish 419 
between their chemical shifts (2.04 – 2.35 ppm and 2.12 – 2.46 ppm[15]) on an in-vivo 1H 420 
MRS examination. Thus, the term ‘Glx’ is used to represent the combined pool of both 421 
metabolites. 422 
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Effect of TBI 423 
During TBI there may be intensive neuronal activation associated with impaired glutamate 424 
reuptake and transport that causes glutamate associated excitotoxicity[32], [68], [69]. Shutter 425 
et al. found combined glutamate and glutamine (Glx) were significantly elevated in occipital 426 
grey and parietal white matter early after injury (7 days) in patients with poor outcome at 6 427 
and 12 months after TBI and combined Glx and Cho ratios predicted long term outcome with 428 
94% accuracy when GCS motor score was included in the model [32].  429 
GABA  430 
GABA is the main inhibitory neurotransmitter of the brain and like glutamate, is stored 431 
intracellularly in neuron vesicles at concentrations of up to 1 mmol / L in the brain [70]. After 432 
release, it is taken up by glia and converted to glutamine via glutamate and fed back to 433 
neurons. Its 1H MRS peak is found between 2.2-2.4 ppm which overlaps with the Glx species 434 
and thus is very difficult to quantify[70], [71]. GABA plays a role in epilepsy and can be 435 
increased in patients with epilepsy by treatment with common anticonvulsants. However, 436 
other studies have shown no difference between patients suffering with epilepsy and normal 437 
healthy controls[70]. GABA quantification can be improved by acquiring the spectra using 438 
specialised GABA-editing techniques such as the pulse sequence MEGA-PRESS[72], [73].  439 
Effect of TBI 440 
GABA normally modulates the excitatory pathways in the brain. Following TBI a loss of 441 
GABAergic neurons disrupts the balance of excitation and inhibition, leading to further cell 442 
injury and apoptosis[74]. An imbalance of GABA and glutamate after TBI may also result 443 
in post-traumatic epilepsy but measurements of GABA are rarely reported in human 1H 444 
MRS studies and GABA has only been shown to fall after TBI by 46 % within 24 hours in 445 
a single animal study.  446 
Lactate 447 
Most of the lactate in the brain is regarded as “glycolytic,” originating from glucose 448 
metabolism via the Embden-Meyerhof pathway, to pyruvate, followed by conversion of 449 
pyruvate to lactate by the action of lactate dehydrogenase (LDH). There is some disparity in 450 
nomenclature about glycolysis in the brain literature, which undoubtedly adds confusion, as 451 
glycolysis culminating in lactate is often termed “anaerobic metabolism,” though often 452 
without supporting evidence regarding the oxygen status in the tissue concerned. In old 453 
studies brain injury was often associated with hypoxia/ischemia (real or assumed), although 454 
modern neurocritical care means that overt hypoxia/ischemia is usually avoided. Even so, 455 
microvascular ischemia appears to exist in some cases[75], as do episodes of hypoxia[76]. 456 
We regard hypoxia as PbtO2 <20mmHg, with severe hypoxia as PbtO2 <10 mmHg. 457 
 458 
The ability of lactate to act as a neuronal fuel has now also been established[6], [77] although 459 
its importance relative to glucose is debated [78]. Lactate may be elevated by hypoxia, 460 
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ischemia or macrophage infiltration[79]. It can appear as a characteristic doublet at 1.3 ppm 461 
when acquired with a long echo time (TE 144 ms), but the MR behaviour of lactate is 462 
complex and lactate signals can virtually disappear or appear inverted depending on MR 463 
conditions[80]. Interpretation of lactate is further complicated by overlap with lipid signals. 464 
Lactate is typically represented by a small peak on 1H MRS despite its relatively high 465 
extracellular concentration of 2.9 mmol / L[81] as its concentration intracellularly,  (which 466 
dominates brain volume  [13], [14]) is much lower.  467 
Effect of TBI 468 
In TBI, the elevation of brain extracellular lactate is known to be associated with poor 469 
prognosis. Although lactate is a normal component of energy metabolism, if lactate appears 470 
elevated in a tissue on 1H-MRS it is usually a sign of pathology. Lactate elevation does not 471 
necessarily indicate hypoxia, as the phenomenon of “aerobic glycolysis” whereby cells 472 
produce lactate despite a seemingly adequate supply of oxygen is well known, e.g. the 473 
Warburg effect in tumours, and a similar effect is seen in TBI, where it is variously termed 474 
metabolic dysfunction, mitochondrial dysfunction, and, in extreme cases, metabolic crisis. In 475 
early work on rat models of TBI there appeared to be an initial rise in brain lactate 476 
hyperacutely following moderate or severe injury, associated with persisting neurological 477 
dysfunction at four weeks [82], [83]. Lactate returned to normal after about 60 minutes, and 478 
there was no association between magnitude of hyperacute transient lactate rise, injury 479 
severity or neurological outcome. However, mild injury that did not result in long term 480 
neurological deficit did not cause any increase in lactate [82]. The hyperacute period is only 481 
addressable in experimental models and study is not feasible in human TBI patients, as 482 
typically an hour or more will have elapsed before they arrive at hospital and longer until a 483 
scan can be performed. In human TBI, lactate elevation can be seen on 1H-MRS in some but 484 
not all instances, illustrated in Marino et al.[50]. Because of the complications with lactate 485 
signals (see above) some 1H-MRS studies of normal and TBI brain do not consider lactate at 486 
all[84]. Lactate elevation is most markedly seen in paediatric head injury[85], [86]. Makoroff 487 
et al showed that in four paediatric TBI patients elevation of lactate measured by MRS was 488 
due to hypoxic-ischemic injury which was associated with worse early neurological outcome 489 
scores[87]. In adult TBI patients, lactate (measured by MRS) is similarly only raised if there 490 
is a severe ischaemic process where it can rise diffusely within 48-72 hours[50] of injury. 491 
This rise can persist for weeks[88] and the degree of lactate elevation may correlate with 492 
outcome at 3 months; higher lactate corresponding to worse outcome[50].  493 
Lipid 494 
Lipids and phospholipids form a group of peaks at 1.3 ppm. When lipid is bound in intact cell 495 
membranes its T2 is too short for detection by in-vivo 1H MRS. Elevated lipid suggests 496 
significant cell membrane disruption so is only visible in severe trauma, such as in shaken 497 
baby syndrome[89]. Lipid measurements are not often reported in adult TBI studies.  498 
 499 
Summary of 1H MRS in TBI 500 
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Following TBI the brain may suffer from significant metabolic failure, direct cell damage, 501 
hypoxia and neuroinflammation. These can be detected non-invasively using 1H MRS, 502 
prompting intervention: metabolic failure signified by NAA reduction may allow a patient’s 503 
metabolic support to be altered by administering an infusion of glucose, or newly developing 504 
metabolic treatments for mitochondrial failure such as succinate[90]. 505 
Prognosticating in acute severe TBI is challenging. Several metabolites, including NAA, 506 
choline, myo-inositol, Glx, lactate and lipid may help predict patients who will not survive or 507 
are likely to survive with the most extreme disability[32], [50], [51], [56]–[58]. 1H MRS can 508 
help clinicians and patients’ families in terms of prognosis. As acute severe TBI typically 509 
results in both a fall in NAA and a rise in Cho that are associated with outcome, the 510 
NAA/Cho may be the most appropriate indicator of injury, distinguishing patients with good 511 
and poor outcome[32].This has the potential to reduce patient and family suffering and 512 
conserve intensive care resources.  513 
The most appropriate region of the brain to be interrogated for prognostication is unclear. CSI 514 
measurements of the subcortical white matter with inclusion of the corpus callosum would be 515 
the most comparable to the literature[29], [50], [51], [56] and the inclusion of single voxel 516 
brainstem NAA measurement would allow MRI invisible injury to this critical structure to be 517 
detected[58]. Other potential targets are the occipital and parietal lobes where changes in Glx, 518 
myo-Inositol and Cho have been correlated with patient outcome. 519 
A summary of the effect of TBI on metabolites interrogated by 1H MRS are shown in Table 520 
2. 521 
 522 
31P MRS 523 
In-vivo 31P MRS detects unbound molecules that contain phosphorus in the human brain. The 524 
most notable of these are the fundamental molecules of chemical energy in all eukaryotic 525 
organisms: adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine 526 
monophosphate (AMP), phosphocreatine (PCr) and inorganic phosphate (Pi). As well as 527 
providing information about energy status, Pi allows measurement of brain pH through 528 
changes in its chemical shift[91]–[93]. Phosphomonoesters (PME) and phosphodiesters 529 
(PDE) are also metabolites that contribute to a standard 31P brain spectrum, and are thought to 530 
represent cell membrane turnover. 531 
Hardware & resolution 532 
MRS detection of 31P is less sensitive than 1H. Comparing the two isotopes, for the same 533 
number of nuclei in the same external magnetic field, the relative sensitivity, also termed 534 
receptivity, is calculated from the NMR sensitivity (proportional to |γ 3 | × I (I + 1)) 535 
multiplied by the natural abundance[15]. Since I (the spin) is ½ for both 31P and 1H, and the 536 
natural abundance is over 99.9% for 1H and 100% for 31P, the gyromagnetic ratio γ is the 537 
crucial factor: 26.752 and 10.831 (units 107 rad T−1 s−1) so relative sensitivity (versus 1H) is 538 
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only 0.065 for 31P, so just 6.5%[15]. In layman’s terms, the gyromagnetic ratio γ, can be 539 
thought of as the strength of the tiny magnets that are the 31P and 1H nuclei, divided by their 540 
spin (value ½ here in both cases) – thus 31P is less sensitively detected than 1H, because the 541 
31P nuclei are weaker magnets than 1H nuclei.  542 
To acquire phosphorus spectra with acceptable signal to noise either larger voxels must be 543 
selected compared with 1H MRS and/or more averages acquired, resulting in longer scan 544 
times. 31P MRS is also limited by the pulse sequences for localisation that can be used: 31P 545 
metabolites have relatively short relaxation times so the transverse magnetisation must be 546 
sampled as quickly as possible after excitation (short TE). Single volume spectroscopy 547 
techniques PRESS and STEAM use multiple echo steps that require long TE, so 31P MRS 548 
localisation is limited to single voxel ISIS and multivoxel CSI in the brain[94]. 549 
The range of chemical shifts that the main metabolites in an in-vivo 31P MRS spectra occupy 550 
is also much wider (≈ 30 ppm) than that of 1H MRS (≈ 5 ppm). The chemical shifts of PCr 551 
and Pi are dependent on pH, and α-ATP and β-ATP on the concentration of free magnesium 552 
(Mg2+). PCr is conventionally considered a reference at 0 ppm (by definition), and the 553 
chemical shifts quoted below represent those from its centre at a pH of 7.2 with normal tissue 554 
Mg2+, as per de Graaf 2007[15]. 555 
High energy phosphates 556 
The high-energy phosphates detected by 31P MRS (PCr, ATP, ADP, AMP & Pi) are directly 557 
connected to each other chemically: the high-energy phosphate group passes from pool to 558 
pool reaching a state of equilibrium depending on the energy expenditure and generation 559 
within the cells. This contrasts with metabolites studied by 1H MRS which are linked to each 560 
other in a broader, biological sense. Thus, the high energy phosphates will be considered as a 561 
group of relative ratios of interconnected metabolites rather than individually. 562 
ATP hydrolysis and generation 563 
ATP is the fundamental molecule of chemical energy in eukaryotic and prokaryotic 564 
organisms and is used and then regenerated with rapid turnover in the brain[95]. The 565 
hydrolysis of ATP into ADP + Pi releases energy that is harnessed to drive the main cellular 566 
processes including the sodium potassium exchanger (Na+/K+ ATPase pump) that maintains 567 
the membrane potential in neurons. The brain maintains ATP at a concentration several fold 568 
higher than that of ADP (average 3 mmol / L vs 0.1 mmol / L[15], [96], [97]) to drive these 569 
processes by continually recycling ADP back to ATP. This is done through glycolysis, the 570 
citric acid cycle and the electron transport chain in mitochondria where the enzyme ATP 571 
synthase catalyses the conversion of ADP and Pi to ATP down a hydrogen ion gradient, 572 
provided oxygen is available as a terminal electron acceptor on complex IV. This cycle 573 
occurs continually so that the human brain, weighing about 1.2 kg, uses an estimated 5.7 kg 574 
of ATP per day[95]. 575 
Creatine kinase 576 
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The process of ATP regeneration via ATP synthase is relatively slow on a cellular scale so 577 
tissues that require energy in bursts such as the brain, skeletal muscle and cardiac muscle 578 
contain creatine and phosphocreatine. Catalysed by the enzyme creatine kinase, 579 
phosphocreatine can very rapidly donate its high-energy phosphate group to ADP, rapidly 580 
regenerated ATP during periods of high metabolic demand independently of oxygen. During 581 
periods of lower metabolic demand the phosphocreatine store is replenished in the 582 
mitochondrial intermembrane space, again by creatine kinase from newly generated ATP. 583 
Phosphocreatine is a spatial buffer for ATP as well as a temporal buffer. Most ATP is 584 
produced in the mitochondria, but used in the cytoplasm. The free diffusion distance of ATP 585 
and ADP are limited by their strong negative charges and low cellular concentrations whereas 586 
PCr and Cr diffuse more freely due to their smaller size, less overall charge, and higher 587 
concentrations. The PCr-Cr system therefore acts as a shuttle linking ATP production in the 588 
mitochondria to its use in the cytoplasm[98]–[100].  589 
31P peaks and their metabolites 590 
The PCr signal, whose chemical shift is defined by convention as 0.00 ppm, is the most easily 591 
identifiable peak in brain 31P MRS. Brain PCr concentration has been reported at 4.0 - 5.5 592 
mmol / L[15] concentrations at reasonably constant levels between grey and white 593 
matter[15], [101], [102]. 594 
The β-ATP peak represents phosphorus in the middle phosphate group; a structure that is 595 
unique to ATP[15]. It would appear to be the most appropriate peak to represent ATP 596 
concentration but its location at extreme upfield (-16.26 ppm) can make it difficult to excite 597 
consistently with a homogenous RF pulse that also covers the other metabolites. 598 
γ-ATP is often used to represent the concentration of ATP, instead of β-ATP. At -2.48 ppm γ-599 
ATP represents the distal phosphate groups of both ATP and ADP, which are effectively 600 
indistinguishable from each other in-vivo due to their similar immediate chemical and nuclear 601 
environment. However, ADP is found at much lower concentrations in the brain (0.1 mmol / 602 
L) than ATP (3 mmol / L)[15], [96], [102] and ADP is regarded as mostly bound up in 603 
vesicles and mitochondria so poorly responsive on MR, making its contribution to the γ-ATP 604 
peak negligible. 605 
α-ATP at -7.52 ppm represents the proximal phosphate groups in ATP and ADP and the 606 
central phosphates of NAD and NADH; these are poorly resolved in most in-vivo MR 607 
spectra. The inclusion of NAD and NADH and its profile slightly further from the centre of a 608 
typical RF pulse makes it an inferior choice to the γ-ATP peak for ATP characterisation[15]. 609 
Inorganic phosphate (Pi) is found at 5.02 ppm as a relatively small peak. Its small size can 610 
make it difficult to accurately integrate, but nevertheless it is often used to express ratios of 611 
brain energy 31P species [103]–[105] . Pi is a useful indicator of intracellular pH, which can 612 
be calculated from the difference in chemical shift between PCr and Pi[92], [106]. Although 613 
Pi is may be a small peak some studies have shown existence of two Pi signals; ascribed to 614 
two pools of Pi differing in pH (ΔpH ~0.4)[107]. In brain, the major (upfield) peak is 615 
assigned as intracellular Pi, and the minor (downfield) peak extracellular Pi, and the two 616 
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signals have different T1 relaxation times, presumably reflecting the different environments 617 
surrounding the phosphate molecules.  618 
Changes after TBI 619 
PCr/ATP and PCr/Pi are two of the most commonly used ratios to express brain energy 620 
status. If the brain is metabolising normally there will be sufficient ATP and plenty of its 621 
short-term high energy store, PCr. However, if the brain is stressed, a plausible scenario is 622 
that it might draw on its store of PCr to maintain ATP homeostasis leading to a reduction in 623 
the PCr/ATP ratio and PCr/Pi ratio. The PCr/Pi ratio will also be affected by a potential 624 
increase in free Pi as ATP is hydrolysed but not remade sufficiently in the mitochondria. 625 
PCr/Pi can be inaccurate with difficulty in reliably measuring the small Pi peak in a 626 
potentially noisy baseline. 627 
Hyperacute 31P MRS studies of TBI are limited to animals for the same reason as 1H MRS. 628 
Ishige et al’s study[104] of focal TBI in rats with sequential measurements after injury 629 
demonstrated a rapid fall in absolute PCr and an increase in absolute Pi in the first 15 mins 630 
after injury. In the absence of further injury these species recovered to near normal within 90 631 
minutes[104]. Further studies by Vink et al. of different grades of injury have demonstrated 632 
the same initial fall in absolute PCr and rise in absolute Pi (or fall in PCr/Pi ratio) which then 633 
recovers within ~100 mins following moderate-severe trauma. There appears to be a second 634 
rise in PCr and fall in Pi and PCr/Pi ratio that occurs 120 mins after injury, remaining 635 
depressed in severe injury [105], [108], [109]. The initial falls in PCr/Pi were associated with 636 
brain acidosis in these studies, but the second falls were not. The degree of this second PCr/Pi 637 
depression four hours after injury correlated with severity of insult, which itself correlated 638 
with 24 hour neurological dysfunction [108]. No studies demonstrated a decrease in ATP 639 
after moderate-severe injury. In the studies that included the most extreme injury severity, a 640 
different pattern was observed: a much greater, persistent fall in PCr and rise in Pi occurred 641 
that did not recover [109]. Unlike animals subjected to more moderate grades of injury these 642 
animals also experienced an irreversible loss of ATP over the three hours following injury 643 
[108], [109]. 644 
The addition of a secondary insult, hypotension, to experimental TBI greatly exacerbated the 645 
metabolic derangement measured by 31P MRS. With moderate hypotension after TBI a much 646 
greater immediate fall was seen in PCr which did not recover as well. Pi increased 647 
significantly more and the immediate acidosis was greater and did not recover as it did in the 648 
absence of hypotension. Importantly, ATP fell significantly in the presence of moderate-649 
severe TBI with hypotension but not with TBI alone. Cells work very hard to maintain ATP 650 
homeostasis at the cost of other metabolites so it appears that a fall only occurs in metabolic 651 
extremis following very severe injury or when TBI occurs with additional hypotensive insult 652 
[104], [108]–[110]. 653 
An in-vivo 31P MRS patient study by Garnett et al.[103] of high energy phosphates in the 654 
subacute period following TBI had different findings to those of the hyper-acute TBI animal 655 
studies above. Seven patients with moderate and severe TBI were studied 9 days (mean) after 656 
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injury: four patients had partially recovered and were self-ventilating whereas three were still 657 
intubated and ventilated. In normal-appearing white matter, a significant increase in PCr/Pi 658 
was found in patients with TBI compared to healthy controls, as was PCr/ATP (although non-659 
significantly). The authors suggested that a possible explanation could be a change in cell 660 
population through reactive gliosis. 661 
These studies suggest that 31P MRS is detecting different changes in brain metabolism 662 
dependent on when, after the injury, the scan is performed. The initial fall in PCr seen in 663 
hyperacute studies in animals (see above) is compatible with the interpretation of cell 664 
membrane injury, K+ efflux from cells and demand on the Na+/K+ ATPase pump that leads to 665 
consumption of PCr. This initial fall in PCr recovered in these animal studies, but the second 666 
fall in the acute stage after two hours did not during the studies and is of uncertain aetiology. 667 
Cellular ATP appears to be maintained following all but the most severe forms of 668 
experimental TBI in animals, likely representing catastrophic energy failure with extreme, 669 
irreversible derangement of all phosphorus metabolites[104], [108]–[110].  670 
Brain pH & Mg2+ concentration 671 
The pH of the brain can be measured from the difference in chemical shift between the Pi and 672 
PCr peaks[91]–[93]. Although the small size of the Pi peak relative to baseline noise can lead 673 
to errors measuring its area, its chemical shift can generally be accurately identified. Changes 674 
in the concentration of hydrogen ions (pH) results in greater or lesser binding of H+ ions to 675 
inorganic phosphate. The presence of the additional hydrogen ions changes the proportion of 676 
protonated to un-protonated inorganic phosphate which changes the mean chemical shift of 677 
the species population. Similarly, the concentration of brain Mg2+ can be calculated from the 678 
difference in chemical shifts between the α-ATP and β-ATP peaks[15], [91], [104], [105], 679 
[111]. 680 
Control of brain pH 681 
Normal neuronal activity causes constant changes in intracellular and extracellular pH in the 682 
brain which are buffered by several mechanisms: the PCr, ATP and creatine kinase system is 683 
one of these. When creatine kinase catalyses the regeneration of ATP from ADP and PCr, a 684 
H+ ion is consumed: ADP + PCr + H+  ATP + Cr. Creatine kinase is strongly pH dependent 685 
and acts as both an ATP and pH buffer in cells with high metabolic workloads. 686 
Effect of TBI 687 
Rodent studies of hyperacute changes in brain pH following severe TBI have found an 688 
immediate, transient fall in pH for the first 15 – 60 minutes following moderate to severe TBI 689 
that is exacerbated by hypotension[82], [104], [105], [112]. The magnitude of this transient 690 
acidosis does not correlate with neurological outcome, histopathological injury or severity of 691 
insult [82] for all but the most extreme (un-survivable) injuries where a progressive, terminal 692 
brain acidosis occurs [109]. Changes in pH accompany changes in PCr/Pi ratio, returning to 693 
normal after an hour and a half in the absence of hypotension. This is what would be 694 
expected from the creatine kinase system, but it is not clear if a fall in PCr causes a shift of 695 
In r vi
w
 20 
the equilibrium, and a rise in H+ ions, or acidification causes a shift in the CK equilibrium 696 
and a fall in PCr. It is perhaps more likely that primary pH changes drive the PCr/Pi change 697 
as the delayed fall in PCr/Pi does not cause a change in pH, suggesting another mechanism.  698 
Intracellular free Mg2+, an important cofactor for glycolysis and oxidative phosphorylation, 699 
has been shown to fall by as much as 60 – 69 % following animal experimental TBI [111], 700 
[113], [114], reaching its nadir between 1 and 4 hours after injury. Free Mg2+ appears to be 701 
particularly sensitive to injury; declining significantly following moderate and even mild 702 
experimental TBI in the absence of changes to PCr, ATP, Pi and pH detected by 31P 703 
MRS[44], [109], [111], [113], [114]. Interestingly, in a graded TBI study performed by Vink 704 
et al free intracellular Mg2+ did not fall in rats subjected to the most severe TBI. This was 705 
attributed to release of Mg2+ from the declining ATP that occurred in this group, replenishing 706 
the total level. After moderate injury Mg2+ appears to recover to baseline after about a week 707 
[44], but its calculation should be performed cautiously when spectra have low signal to noise 708 
as previous reported changes have been shown to be due to errors of chemical shift 709 
assignments[91].The subacute study by Garnett et al. of patients with moderate to severe TBI 710 
found white matter was more alkaline (higher intracellular pH) and had higher free 711 
intracellular Mg2+ in TBI patients 2– 21 days (mean 9 days) after injury compared to healthy 712 
volunteers[103]. A difference in grey matter pH was not found, although grey matter 713 
PCr/ATP was significantly higher in TBI brain than in healthy controls[103]. Conversely, 714 
measurements of brain extracellular pH (not using MRS, but using intracranial probes) 715 
following severe TBI in humans suggest that lower pH is associated with a worse 716 
outcome[115], [116]. The relationship between brain extracellular and intracellular pH in 717 
human TBI is unclear.  718 
 719 
Phosphomonoesters & phosphodiesters 720 
The cell membrane phospholipid bilayer in the brain is not visible on 31P MRS because its 721 
magnetization decays too quickly for detection. Its precursors the phosphomonoesters 722 
(PMEs) phosphorylethanolamine (PE) and phosphorylcholine (PC), are visible at 6.78 ppm 723 
and 5.88 ppm in high quality spectra [15], [103]. Phosphodiesters (PDEs) glycerol 3-724 
phosphorylethanolamine (GPE) and glycerol 3-phosphorylcholine (GPC), at 3.2 ppm and 2.8 725 
ppm, are produced by phospholipase breakdown of cell membranes. They are then converted 726 
to PMEs by phosphodiesterase. Consequently, the ratio of PME/PDE is thought to be an 727 
indicator of cell membrane turnover[94], [97], [117]. 728 
Changes in the ratio of PME/PDE is often explored in 31P MRS studies of TBI but the small 729 
size of the peaks compared to baseline noise means that statistically significant differences 730 
often cannot be found even if they are present[103]. It should be noted however that the 731 
phosphorus nuclei in PMEs and PDEs are coupled to hydrogen atoms which causes splitting 732 
of their resonances which can be exploited with the polarization transfer technique and proton 733 
decoupling to significantly enhance their detection[15] 734 
 735 
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Confounders of 31P MRS measurements in the brain 736 
Regional variations of high energy phosphate species in the human brain exist that influence 737 
the results obtained by 31P MRS studies. Whereas the concentration of PCr remains relatively 738 
constant throughout the brain, the PCr/ATP is higher in grey matter (GM = 1.19) than white 739 
matter (WM = 0.84)[118] because of the higher concentration of ATP found in white matter 740 
(GM = 2 mmol / L; WM = 3.5 mmol / L)[15]. GM also has a higher metabolic rate than WM, 741 
using three times as much ATP and consuming 77% of total energy expenditure of the brain 742 
despite representing only 55% by tissue weight[118]. 743 
PCr is known to vary with age in healthy volunteers: increasing age is associated with 744 
slightly higher PCr, lower PME and a slightly more acidic brain[119]. There is also an 745 
inverse relationship between body mass index and absolute measures of PCr and ATP but as 746 
these changes are equivalent there is no resulting change in PCr/ATP ratio[120]. 747 
If patients with acute severe TBI are studied whilst intubated, sedated and ventilated the 748 
effect of anaesthetic agents should also be considered. There is evidence that phenobarbital 749 
increases the PCr of rat brain but does not change ATP or ADP, measured by biochemical 750 
assays on tissue extracts[121]. Halothane, nitrous oxide and fentanyl do not seem to have any 751 
effect on high energy phosphates concentrations [121].  752 
Magnetization transfer technique 753 
As well as measuring static concentrations of phosphorus metabolites (absolute and ratios), 754 
flux from one pool to another can be measured using the magnetization transfer (MT) 755 
technique. MT is technically challenging compared to ‘standard’ 31P MRS.  The basis of MT 756 
is selective saturation or inversion of a resonance of one moiety which undergoes chemical 757 
exchange to another.  If the rate of exchange is fast compared to T1, then the saturation or 758 
inversion is transferred; quantification of exchange rates requires a knowledge of the T1 and 759 
MT rate[122]. MT can provide information on the flux between PCr and ATP and hence the 760 
rate of creatine kinase[123], [124]. Similar methodology has also been applied to assess the 761 
flux between Pi and ATP to estimate ATP synthesis rate in brain[107], [125].  However, 762 
concern surrounds this technique as ATP synthesis rates from MT transfer are significantly 763 
higher than the rates of oxidative ATP synthesis measured by other techniques, shown in 764 
muscle, heart, and liver[126], [127]. This discrepancy is usually attributed to rapid Pi-ATP 765 
exchange via glycolysis, that can produce significantly higher MT measures of Pi->ATP flux 766 
compared with net oxidative Pi->ATP flux[126], [128], [129]. Although this does not 767 
necessarily invalidate MT measures of ATP synthesis rates in brain[125], [130], where 768 
average measures agree with rates calculated indirectly from previously reported cerebral 769 
metabolic rate of glucose consumption[125], varying levels of anaesthesia in TBI may also 770 
influence results. 771 
 772 
 773 
 774 
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Therapeutic and prognostic potential 775 
31P MRS studies have shown changes in PCr, Pi, pH and Mg2+ in the brain following TBI 776 
with ATP being relatively unaffected, except for under extreme stress in experimental TBI, 777 
and timing of when after injury a 31P MRS study can be performed is key.  778 
In a clinical setting 31P MRS cannot be performed in the hyperacute period after injury 779 
because of the time required transferring a patient to hospital and stabilising them. However, 780 
if a patient displayed severely depressed PCr/Pi and pH measured by 31P MRS on the day of 781 
injury, this may suggest that the initial injury was extreme, or compounded by a period of 782 
hypotension, which may or may not have been known about. As well as prompting 783 
meticulous control of cerebral perfusion pressure, causes for hypotension could be 784 
investigated if they were not already apparent. 785 
The degree of PCr/Pi depression may also correlate with outcome, if performed on the day of 786 
injury, as seen in animal studies [108], [109], [112]. However, there is a paucity of outcome 787 
data from 31P MRS animal studies reporting changes in PCr or Pi performed more than 12 – 788 
48 hours after injury, in what would be a more achievable timeframe clinically. However, as 789 
mentioned above, the situation with human TBI patients seems to differ from animal studies, 790 
with human TBI causing a higher PCr/ATP or PCr/Pi ratio than healthy controls, and TBI 791 
resulting in a more alkaline brain pH when performed 4 - 21 days after injury. If the Pi peak 792 
is not distinguishable from baseline noise, PCr/ATP could be used as an alternative ratio but 793 
in the event of equivalent fall in both PCr and ATP species following TBI with hypotension 794 
or extreme injury could (in principle) lead to no change in their relative ratio 795 
(PCr/ATP)[103].  796 
31P MRS studies performed in the acute to subacute period after injury that display an 797 
elevation in the PCr/Pi and PCr/ATP ratios may represent neuroinflammatory changes in 798 
TBI[103], and merits further investigation. Further study is ongoing characterising these 799 
changes and their pathophysiological basis. 800 
Although brain free intracellular Mg2+ appears to be very sensitive to injury in the acute and 801 
subacute period following TBI, it does not easily distinguish between moderate and severe 802 
grades of injury. Whereas there may be a greater fall in Mg2+ following moderate-severe 803 
injury than mild injury, paradoxically there is no change following extreme injury [109]. 804 
A summary of the effect of TBI on metabolites interrogated by 31P MRS are shown in Table 805 
3. 806 
 807 
 808 
 809 
 810 
 811 
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13C MRS 812 
Hardware and sensitivity 813 
Whereas in-vivo 1H MRS measures brain metabolites by detecting the hydrogen atoms within 814 
these molecules, 13C MRS does so by detecting the 13C isotopes in their structure. 13C MRS is 815 
much less sensitive 1H MRS as only 1.1 % of naturally occurring carbon is the MR visible 816 
isotope 13C and most organic molecules contain many more hydrogen atoms than they do 817 
carbon atoms. The Larmor (natural) frequency of 13C is also a quarter of that of 1H, so each 818 
atom releases much less energy when it relaxes to be detected by the scanner. These factors 819 
combine to give 13C MRS a sensitivity of only 0.018 % of that of 1H MRS[15]. Consequently 820 
in-vivo 13C MRS studies are almost always performed with an infusion of 13C enriched 821 
metabolites to boost the signal from the brain but even so large voxels are typically used to 822 
acquire as much signal as possible. 823 
Methods of detection, localisation and decoupling 824 
The sensitivity of 13C can be further improved by a variety of techniques that use the 825 
interactions of 1Hs naturally bonded to the 13C nuclei. Nuclear Overhauser enhancement 826 
(NOE) and polarization transfer are two different techniques for increasing signal that 827 
transfer some spin polarization from 1H to 13C. Proton decoupling is another important 828 
technique as J-coupling of 13C nuclei to their bonded 1Hs causes splitting of metabolite peaks 829 
into complex patterns of small multiplets that can be difficult to interpret. This interaction can 830 
be broken using proton decoupling at the same time as applying either NOE or polarization 831 
transfer, further improving spectral resolution[15], [20]. 832 
As well as directly detecting the 13C in a metabolite, 13C MRS can be performed indirectly 833 
through detecting the effects of the 13C on the 1Hs that are bonded to it. termed 1H-observe 834 
[13C-edited] spectroscopy, or proton-observe carbon edited (POCE) spectroscopy.  POCE 835 
increases the sensitivity even more than using the polarisation transfer technique (almost to 836 
that of 1H MRS) and directly provides 13C fractional enrichment values[20]. This increased 837 
sensitivity however comes with the narrow spectral range of the 1H MRS scale (5 ppm) 838 
where many peaks overlap, so resolving individual peaks can be more difficult. Crowding of 839 
the spectra is much less of a problem with the great spectral range of direct 13C MRS 840 
detection (200 ppm). Also,13C nuclei which do not have 1H attached, such as the carboxylate 841 
carbon in glutamate and glutamine can be measured by direct 13C MRS while they cannot be 842 
measured with the indirect (POCE) MRS technique.  843 
Proton decoupling, NOE, polarization transfer or indirect detection require a 1H channel in 844 
addition to the 13C channel on the RF head coil[20]. A complex sequence of pulses must be 845 
passed down each channel in quick succession which can result in current induction from one 846 
channel to the other, introducing further noise in the spectrum if appropriate arrangement of 847 
these coils with effective filtering is not observed. 848 
The RF pulses for broadband proton decoupling deposit a significant amount of energy into 849 
the patient, causing tissue heating. The relevance of tissue heating depends on how thermally 850 
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sensitive the tissue is, and by how much it is heated. The specific absorption rate (SAR) limit 851 
to minimize heating of tissue is critical with regards to the eyes; so 13C MRS with proton 852 
decoupling is typically performed using surface coils to address ROIs of the brain that avoid 853 
them. 854 
Due to the abundance of carbon atoms in the long fatty acid chains of subcutaneous scalp 855 
lipids, non-localised 13C spectra of the brain are dominated by large lipid peaks at 20 – 50 856 
ppm. Glycerol that forms their lipid backbone also produces pronounced, but smaller, peaks 857 
at 63 and 73 ppm. These scalp peaks must typically be excluded with voxel selection or outer 858 
volume suppression for brain metabolites to be measured. Furthermore, the chemical shifts of 859 
some key metabolites place them within the lipid range of 20 – 50 ppm meaning that voxel 860 
selection must be rigorous. The high concentration of lipid in cerebral white matter does not 861 
pose the same problem as it is bound up tightly in myelin so its MR signal decays too rapidly 862 
for detection by in-vivo 13C MRS[131]. 863 
Glycogen 864 
Despite glycogen’s large size (106 - 107 Da[132]) it is freely mobile and found in the human 865 
brain at concentrations of 5 mM / kg in glia[133] so it is the only brain metabolite of interest 866 
visible on 13C MRS natural abundance studies using reasonable scan times. It is thought to be 867 
100 % MR visible[134] with a peak at 100 ppm, split by bonded 1Hs if 13C spectra are 868 
acquired without proton decoupling. Brain glycogen measured by enzymatic extraction has 869 
been shown to increase in regions of focal injury after experimental TBI in rats compared to 870 
uninjured regions, but it is not known if this correlates with degree of histological injury or 871 
outcome[135]. 872 
Dynamic studies of glucose, lactate, glutamate and glutamine 873 
Most 13C MRS studies of human brain metabolism involve infusion of 13C enriched 874 
metabolically active substrates and detection of that signal as it makes its way sequentially 875 
through different metabolic pools. The most commonly studied substrate in the brain is 1-13C 876 
glucose: As it is infused it appears in the brain at 94 and 98 ppm (α and β isoforms). It is then 877 
metabolised to lactate by glycolysis (principally), producing a lactate peak at 22 ppm in the 878 
brain spectra. The 13C label is then incorporated into the TCA cycle where it is spun out from 879 
alpha-ketoglutarate as glutamate, detectable at 34 ppm. 13C glutamate is released from 880 
neurons and taken up by glia where it is converted into glutamine [5], detected at 32 ppm. 881 
Using mathematical models and certain assumptions, the rate of brain glucose uptake can be 882 
calculated from the appearance of glucose, the rate of glycolysis from the appearance of 883 
lactate, the TCA cycle rate from the appearance of glutamate and neuronal-astrocyte coupling 884 
by the appearance of glutamine[5], [15], [136]. Alternative labelling patterns of glucose can 885 
be used, such as 2-13C and U-13C6 glucose that share identical biological effects but produce 886 
different spectra. There are benefits and limitations for each[20]. Dynamic 13C studies can 887 
also be performed using 13C acetate and 13C beta-hydroxybutyrate. Acetate is predominantly 888 
metabolised by the glia, allowing the metabolic rates of this specific cell population to be 889 
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measured[5], [20] whereas beta-hydroxybutyrate is predominantly metabolised by neurons 890 
during periods of fasting when it supplies 60% of the fuel for brain[5]. 891 
PET studies of brain metabolism using [18F]-fluorodeoxyglucose can measure the brain’s 892 
uptake and phosphorylation of glucose, but are unable to follow its metabolism further 893 
downstream: 13C MRS measures glucose uptake, but also the TCA cycle rate and neuronal-894 
glial coupling. Changes in the rate of the TCA cycle and glutamate/glutamine cycling have 895 
been reported following stroke, Alzheimer’s disease and diabetes mellitus[5]. No 13C infusion 896 
studies of human TBI have been reported to date, although the technique has potential to shed 897 
light on the effects of TBI on these key processes.  898 
13C hyperpolarisation 899 
13C hyperpolarisation is a technique that transiently increases the signal from 13C nuclei ten 900 
thousand-fold[137], allowing detection of 13C metabolites in a short timeframe. Without 901 
performing hyperpolarisation, nuclear polarization is poor because the energy required to 902 
align a nuclear spin against a magnetic field is so small that thermal fluctuations can easily 903 
overpower these transitions despite using large magnetic fields. Although various 904 
hyperpolarisation methods exist, the version implemented for clinical studies is dissolution 905 
Dynamic Nuclear Polarization (DNP). The following description is from Nelson et al. 906 
(2013)[138]. “Hyperpolarized 13C MRI is a relatively new molecular imaging technique with 907 
an unprecedented gain in signal intensity of 10,000- to 100,000-fold[137] that can be used to 908 
monitor uptake and metabolism of endogenous biomolecules[139], [140]. The magnitude of 909 
the increase in sensitivity depends on the degree of polarization that is achieved, the T1 910 
relaxation time of the 13C agent, the delivery time, and the MR methods applied. 911 
Hyperpolarized agents are generated by mixing 13C-labeled compounds with an electron 912 
paramagnetic agent (EPA), placing them in a 3.35-T magnetic field, cooling to ~1 K, and 913 
using microwaves to transfer polarization from the electron spin of the EPA to the 13C nuclei 914 
of the biomolecule (13). Once the polarization has reached the required level, the sample is 915 
rapidly dissolved with hot, sterile water and neutralized to physiological pH, temperature, and 916 
osmolarity. Intravenous injection of the hyperpolarized solution and observation using 13C 917 
MR allow its delivery and metabolic products to be monitored (15). The data must be 918 
obtained as rapidly as possible after dissolution because the enhancement decays at a rate 919 
determined by the T1 relaxation time of the agent, which is about 60 s for [1-13C] pyruvate at 920 
3 T. Translation of hyperpolarized technology into human subjects has been challenging 921 
because it requires specialized instrumentation to prepare the agent in a sterile environment, 922 
filter out the EPA, perform quality control (QC), and rapidly deliver samples to the patient”. 923 
DNP works best for metabolites with carboxylate carbons which have long T1 so polarization 924 
decays more slowly; clinical studies typically use [1-13C] pyruvate, such as the first-in-human 925 
study that interrogated the metabolism of prostate cancer[138]. To date, no 13C 926 
hyperpolarization studies in human TBI brain have been published. 927 
A 13C hyperpolarization study of rat TBI has recently been performed by DeVience et al. 928 
using 1-13C pyruvate[141]. Controlled cortical impact of rat brain produced lower 929 
13C-bicarbonate signals and higher 1-13C] lactate in traumatised regions of brain than non-930 
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traumatised brain. This correlated with cortical scarring and persisting cell death on 931 
histological analysis performed 30 days after injury. This suggests a shift from oxidative to 932 
non-oxidative metabolism due to TBI, in the absence of gross hypoperfusion, as no difference 933 
in [1-13C] pyruvate signal was seen in the traumatised region. Surprisingly, sham operated 934 
animals who underwent craniotomy but no intentional cortical injury showed much less 935 
significant but similar changes to those exposed to cortical impact. In mice, a 13C 936 
hyperpolarisation study with 1-13C pyruvate, performed 12 hours after controlled cortical 937 
impact to brain showed an increase in the 1-13C lactate / 1-13C pyruvate ratio detected with in-938 
vivo 13C MRS in the injured hemisphere compared to the contralateral uninjured 939 
hemisphere[142]. 940 
Conventional (non-hyperpolarized) 13C MRS studies that rely on the infusion of 13C enriched 941 
substrates detect downstream metabolites of the substrates infused. Hyperpolarized studies 942 
are much more limited due to the very transient nature of hyperpolarization enhancement of 943 
13C MRS signal so only metabolites a few steps downstream can be detected before the 944 
hyperpolarized effect is lost. Hyperpolarisation and conventional 13C MRS labelling studies 945 
can be considered complementary as they address metabolic pathways on different 946 
timescales.   947 
Summary of 13C MRS and clinical role 948 
Despite the potential of 13C enriched steady-state infusion studies to shed light on the 949 
biochemistry of TBI, we do not currently see it as a routine clinical tool in the management of 950 
TBI, due to the extensive time required in the scanner for data acquisition, large volumes of 951 
expensive 13C-labelled infusates required and complex post-acquisition analysis. However, 952 
conceivably 13C isotope costs may come down in future, scanners become more sensitive, 953 
simpler data analysis strategies devised, and workarounds adopted such as starting the 954 
infusion outside of the magnet to reduce the time the patient is inside. Other possibilities are 955 
natural abundance (unlabelled) studies of brain glycogen that may show changes related to 956 
TBI, but few studies to date have demonstrated this and the scan times required are also 957 
long[20], [133]. 958 
Hyperpolarized 13C MRS shows great potential in the monitoring of brain metabolism for the 959 
clinical management of TBI. The short acquisition time and clear signal it produces puts it on 960 
par with 1H MRS, although 13C hyperpolarization has the downside of expensive 961 
13C-substrate and hyperpolarization equipment, and larger team of expert staff necessary.  962 
Metabolic derangement by elevated lactate/pyruvate or lactate/bicarbonate ratios can be 963 
mapped throughout the brain unlike techniques such as microdialysis, which only sample 964 
from a single region of brain which may miss key regions where brain energy is failing. As 965 
targeted therapies for brain injury become available they may be delivered focally to regions 966 
of metabolic dysfunction. In-vivo 13C hyperpolarization is still a relatively new technique and 967 
development and further advances are expected.  968 
 969 
 970 
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Practical considerations: MR conditional equipment and risks 971 
Taking critically ill patients with acute severe TBI for an MR study can be challenging; 972 
patients typically have multiple monitoring devices and require intensive support. However, 973 
with the use of MR conditional ventilators, syringe drivers and an appropriate ICP monitor 974 
set-up a patient’s critical care bed can effectively be recreated inside the MR suite. 975 
Equipment MR compatibility is graded. Whereas plastic ventilator tubing is MR safe at any 976 
field strength and is called ‘MR Safe’ a mechanical ventilator may be suitable to use at 3T 977 
but not at 7T: ‘MR conditional’. Even if it is designed to be used with a 3T scanner, often that 978 
allows it to be taken into the room, but not right up to the magnet bore where the magnetic 979 
field is strongest. Ventilator extension tubing must be prepared to reach the patient. 980 
As well as the projectile risk of ferrous objects, an item’s MR conditional status depends on 981 
its performance within the MR environment. Both the changing gradient magnetic fields used 982 
for localisation and the power and frequency of the RF pulses can cause induction of current 983 
in non-ferrous metals. This is greatest when the length of the object, commonly a wire, is a 984 
multiple of the wavelength of the RF pulse[143]. Furthermore, the ventilator or patient 985 
monitor can produce electromagnetic interference that will affect the image or spectra 986 
quality. 987 
An important example of this for patients suffering from TBI is the commonly used Codman 988 
MircoSensor ICP Transducer (Codman & Shurtleff, Inc.). When using the body (main 989 
scanner) coil to transmit and a head coil to detect at 3T, the electrical current that is induced 990 
is sufficient to heat the wire and damage the probe. This necessitates replacement of the 991 
probe, and consideration of potential burns to the patient’s skin and brain that are in contact 992 
with the wire. This effect can be stopped by looping the extra length of wire away from the 993 
patient’s skin which introduces a radiofrequency choke that limits current induction[144]. 994 
This allows safe use of the microsensor in a 3T scanner during MR data acquisition. Two 995 
other monitoring devices that are often used in the management of acute severe TBI cannot 996 
be used during an MRS study: brain tissue oxygen probes (such as Licox®) and microdialysis 997 
pumps. Licox catheters must be disconnected with their connecting lead but the attached 998 
intracranial probe can generally be left in place for reconnection after the study. 999 
Microdialysis catheters may similarly be left attached but the battery that drives the pump is 1000 
MR unsafe, so must be removed. Whereas these two monitoring systems are useful for 1001 
clinical management, a brief hiatus is rarely critically disruptive and probably outweighed by 1002 
the information that MRI and MRS studies provide. 1003 
Other specific items that are a projectile risk in the static magnetic field, are at risk of current 1004 
induction causing burning or rotational injury due to changing magnetic fields include: 1005 
pacemakers and their leads, ECG wires and dots, deep brain and spinal cord stimulation 1006 
leads, patient oxygen cylinders, some cerebral aneurysm clips and metal fragments in 1007 
patients’ eyes. If these are present and non-removable (such as an implanted pacemaker) they 1008 
will preclude examination by MRS/MRI. In the acute period after a severe TBI it is difficult 1009 
exclude a history of a metal fragment in a patient’s eyes but in practice these would have 1010 
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been detected or excluded on CT examination at presentation for acute TBI. Some tattoos and 1011 
permanent eyeliners may also be heated by the RF pulses but these are often not an absolute 1012 
contraindication to examination by MR. The issue of guarding against tissue heating is not 1013 
just confined to metal fragments but also to uncontaminated tissue and has been mentioned 1014 
above. 1015 
Head coils that completely envelope the head make it difficult accessing the patient’s airway 1016 
in an emergency. Head coils with joins that can open-up, either hinged along one side, or else 1017 
with a front half that can be detached completely (see Fig 4B), allow access to the airway in 1018 
an emergency and make correctly positioning the patient’s head within the head coil easier. 1019 
This is even more relevant when the patient has prominent intracranial monitoring. A 1020 
potential obstacle to performing MR studies on patients with acute severe TBI is the lack of 1021 
head elevation that can be achieved during the scan. This is even more restricted by volume 1022 
head coils. Head elevation to 30 degrees is an effective initial treatment step in the 1023 
management of raised ICP[145], but only up to 5 degrees of head elevation can be achieved 1024 
with padding inside a head coil. Patients with very brittle raised ICP on maximum therapy 1025 
must wait before an MRS study can be performed if they will not tolerate any period lying 1026 
flat. 1027 
 1028 
Summary, conclusions & future prospects 1029 
1H, 31P and 13C in vivo MRS are complementary techniques that allow non-invasive 1030 
measurement of different aspects of brain metabolism that may contribute to the clinical 1031 
management of patients with acute severe TBI (see Fig 5). 1032 
13C MRS measures ‘upstream’ brain energy metabolism: the breakdown of infused 13C 1033 
labelled glucose (or other sugars) via glycolysis and the TCA cycle. To date few studies of 1034 
13C MRS in TBI exist, but the development of in-vivo hyperpolarized techniques shows 1035 
promise in this field. 31P MRS allows measurement of ‘downstream’ metabolism by detecting 1036 
high energy phosphates (ATP and PCr) produced by oxidative phosphorylation and creatine 1037 
kinase in mitochondria. Changes in these metabolites have been noted in a few human and 1038 
animal studies of TBI but further study is required. 1039 
1H MRS is the most commonly used MRS technique for studying brain metabolism following 1040 
TBI. It has the potential to measure a variety of metabolites: some are associated with 1041 
‘upstream’ brain energy metabolism such as lactate, glutamate and glutamine, whose flux can 1042 
also be measured by 13C MRS. Creatine and NAA are associated with the ‘downstream’ 1043 
metabolism of ATP and PCr, which can also be measured with 31P MRS. Free brain lipid and 1044 
choline are not as directly linked to brain metabolism and are likely markers of cell 1045 
membrane damage. 1H MRS has shown great potential as an additional prognostic tool for 1046 
patients with acute severe TBI, but the region of the brain that should be studied and how 1047 
long after injury it should be performed is debatable[146]. The development of standardised 1048 
protocols of acquisition and analysis would facilitate its progression into clinical care. 1049 
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MRS has potential to play a bigger role in Phase II trials of therapies by providing surrogate 1050 
markers and “tissue fate” measures that can help determine efficacy and inform whether a 1051 
larger Phase III trial would be worthwhile or not. 1052 
Finally, the non-invasive (or minimally invasive) nature of MRS makes it an ideal technique 1053 
for follow-up of patients post-TBI. There is evidence to suggest that TBI produces long-term 1054 
changes in the brain and that neurodegeneration occurs, with earlier onset of pathologies such 1055 
as Parkinson’s and Alzheimer’s disease[147]. Better understanding of brain biochemistry 1056 
may help development of better therapies. MRS is uniquely placed to shed light in such 1057 
investigations. 1058 
 1059 
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 1585 
Figure Legends 1586 
Figure 1 1587 
Simplified schematic of major energy pathways in the brain includes glycolysis, which takes 1588 
place in the cytosol and produces pyruvate, which enters mitochondria and is converted into 1589 
acetyl CoA that enters the TCA cycle. Alternatively, pyruvate can stay in the cytosol and is 1590 
converted into lactate that is exported out of the cell. The pentose phosphate pathway (PPP) 1591 
takes place in the cytosol and is an alternative pathway that can be upregulated after injury; it 1592 
is an important source of NADPH used to produce the reduced form of glutathione (GSH) for 1593 
preventing oxidative stress. This figure was originally published by Carpenter et al. in Eur J 1594 
Pharm Sci 57 (2014) 87–97. © 2014 The Authors. Published by Elsevier B.V. Open Access 1595 
under a CC–BY licence[4]. 1596 
 1597 
Figure 2 1598 
1H MRI (T2W axial slice) and 1H MRS CSI (TE 135 ms, TR 2200 ms, 3 averages, 4:41 mins 1599 
acquisition time, 200 ms Hanning filter) of healthy control (A), and patient with acute severe 1600 
traumatic brain injury after craniectomy(B) acquired with a 12 channel 1H volume coil on a 1601 
Siemens 3T scanner, data analysis performed with Siemens Syngo software. A demonstrates 1602 
the position of the selected voxel (blue square, †), represented in C, within the CSI grid 1603 
(hidden). C, 1H spectrum of 10 x 10 x 15 mm voxel † from healthy volunteer A. D, 1H 1604 
spectrum of 8 x 8 x 15 mm blue square voxel ‡ of patient B, within the CSI grid (hidden). 1605 
Metabolite peaks are annotated in C and D: Cr, creatine; Cho, choline; NAA, 1606 
N-acetylaspartate, chemical shift on the x-axis in ppm, signal intensity on y-axis using 1607 
arbitrary units. Unpublished images by Tonny V. Veenith, courtesy of the Wolfson Brain 1608 
Imaging Centre, Cambridge, UK. 1609 
 1610 
Figure 3  1611 
1H MRI and 31P MRS CSI (TE 2.30 ms, TR 4000 ms, 25 mm voxels, 30 averages, 18 mins 1612 
acquisition time, 200 ms Hanning filter) of patient with acute severe traumatic brain injury 1613 
acquired with a 31P birdcage volume coil (PulseTeq, Chobham, Surrey, UK) on a Siemens 3T 1614 
scanner, data analysis performed with Siemens Syngo software. A, Axial FLAIR image 1615 
demonstrating decompressive craniectomy on patient’s right side with associated regions of 1616 
high signal in that hemisphere. B, axial T2 HASTE acquired with 1H channel on a 31P coil 1617 
overlaid with 31P MRS CSI grid of 8 x 8, 25 mm cubed voxels. Each voxel contains the 1618 
spectrum from its volume. C&D, 31P spectrum from voxel †(D) and ‡(C) of image 5A with 1619 
phosphorus peaks annotated. Species can be identified by their chemical shift on the x-axis in 1620 
ppm. Signal intensity on y-axis using arbitrary units. Unpublished images by the authors, 1621 
courtesy of the Wolfson Brain Imaging Centre, Cambridge, UK. 1622 
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Figure 4 1623 
(A) Example of a 13C surface coil (Rapid Biomedical GmBH, Rimpar, Germany) with 1624 
flexible design, allowing it to come in closer contact to the patients’ head. Here it is 1625 
positioned to sample the occipital lobe. The coil contains a 13C channel and 1H channel within 1626 
its housing. 1627 
(B) Example of a 31P birdcage volume coil (PulseTeq Ltd, Chobham, Surrey, UK) which can 1628 
be opened, allowing to access a patient’s head. The coil also contains a 1H channel for 1629 
imaging to allow spectral localisation. 1630 
 1631 
Figure 5 1632 
Simplified schematic of different metabolites and processes in the brain that can be 1633 
interrogated using 1H MRS, 31P MRS, 13C MRS and DNP 13C MRS. 1H and 31P MRS show 1634 
endogenous metabolites; 13C MRS requires exogenous 13C-enriched substrate, while for DNP 1635 
13C MRS the exogenous 13C-enriched substrate is hyperpolarized before administration, 1636 
transiently boosting 13C signal. Pathways include uptake of glucose that is metabolised via 1637 
glycolysis in the cytosol (with a low yield of ATP per mole of glucose consumed) producing 1638 
pyruvate. Pyruvate can enter mitochondria where it is converted into acetyl CoA that enters 1639 
the TCA cycle. Pyruvate remaining in the cytosol can be converted into lactate, 1640 
simultaneously recycling NADH into NAD+ allowing glycolysis to continue. The rate of 1641 
glucose uptake and glycolysis can be interrogated with 13C MRS (glucose, lactate 1642 
appearance) whereas the relative flux of “anaerobic” metabolism vs. aerobic mitochondrial 1643 
metabolism can be measured with DNP 13C MRS (lactate vs. HCO3-) and 1H MRS (lactate). 1644 
The TCA cycle drives the mitochondrial electron transport chain for high-yield ATP 1645 
synthesis. The rate of the TCA cycle can be calculated by the rate of appearance of 13C 1646 
labelled glutamate (13C MRS) and ATP produced measured with 31P MRS (γ-ATP, β-ATP, 1647 
Pi). Neuronal integrity and mitochondrial function can be measured indirectly by detection of 1648 
NAA with 1H MRS (and 13C MRS). Neuronal-glial coupling is represented by glutamate-1649 
glutamine cycling detected by 13C MRS, whereas total combined glutamate and glutamine 1650 
that may be raised in pathological excitotoxicity can be measured with 1H MRS. Cell 1651 
membrane integrity and damage and turnover may be represented by 1H MRS (choline, lipid) 1652 
and 31P MRS (PME/PDE ratio), which also can detect the balance and consumption of high 1653 
energy phosphates (ATP, PCr, Pi). Further details of the above, and other MRS-detectable 1654 
molecules (including creatine, myo-inositol, glycogen and nicotinamide-adenine 1655 
dinucleotides), can be found in the text. Abbreviations: ADP, adenosine diphosphate; ATP, 1656 
adenosine triphosphate; Cr, creatine; DNP, dissolution dynamic nuclear polarization; GABA, 1657 
gamma-aminobutyric acid; NAA, N-acetylaspartate; MRS, magnetic resonance spectroscopy; 1658 
NAD+, nicotinamide adenine dinucleotide oxidised form; NADH, nicotinamide adenine 1659 
dinucleotide reduced form; PCr, phosphocreatine; PDE, phosphodiesters; PME, 1660 
phosphomonoesters; Pi, inorganic phosphate; PPP, pentose phosphate pathway; TCA, 1661 
tricarboxylic acid. 1662 
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 1664 
Tables 1665 
 1666 
Isotope Gyromagnetic 
Ratio (MHz T-
1) 
Larmor 
frequency at 3 
T (MHz) 
Natural 
Abundance 
(%) 
Relative 
Sensitivity 
1H 42.58 127.74 99.99 1 
31P 17.24 51.72 100.00 0.0665 
13C 10.71 32.13 1.11 0.00018 
 1667 
Table 1. Hydrogen, phosphorus and carbon gyromagnetic ratio, Larmor frequency at 3T, % 1668 
natural abundance and relative sensitivity to 1H MRS accounting for % natural abundance of 1669 
the isotopes and Larmor frequency, but not natural concentration of biomolecules in the 1670 
brain. Adapted from de Graaf, In Vivo NMR Spectroscopy (2007) [15] 1671 
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 Spectrum 
Peak 
Physiology Change in 
Acute TBI 
Change in 
Chronic 
TBI 
Correlation to 
prognosis 
NAA 2.02 ppm Neuron viability ↓↓ ↓  
Creatine 3.02 ppm ATP generation and energy 
metabolism 
↔   
Choline 3.24 ppm Cell membrane turnover ↑↑ ↑  
myo-Inositol 3.5 ppm Osmoregulation ↑   
Glx 
(glutamate+ 
glutamine) 
2.2-2.4 
ppm 
Excitatory neurotransmitter 
(glutamate) 
↑↑   
Lactate 1.33 ppm Mitochondrial dysfunction ↑   
GABA 2.2-2.4 
ppm 
Inhibitory neurotransmitter ↓   
Lipid 1.3 ppm Cell membrane ↑   
Table 2. Summary of metabolite changes following TBI detectable with in-vivo 1H MRS. ↑:  1674 
increase in metabolite; ↓: decrease in metabolite; ↔: no significant change or insufficient 1675 
data; : potential clinical use as a prognostic predictor; ppm: parts per million. 1676 
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 Changes in 
hyperacute 
Stage* 
Changes in 
subacute Stage 
Correlation 
to prognosis 
Metabolites associate 
with energy 
metabolism 
↓ PCr ↑ PCr/ATP  
↑ Pi   
↓ PCr/Pi ↑ PCr/Pi * 
Change in pH ↓   
Mg2+ ↓† ↑↓ *† 
Table 3. Summary of metabolite changes following TBI detectable with in-vivo 31P MRS. ↑:  1679 
increase in metabolite; ↓: decrease in metabolite; : potential clinical use as a prognostic 1680 
predictor; * indicates animal studies. † In animal studies Mg2+ falls proportionally to injury 1681 
severity, except for following the most severe TBI. 1682 
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